Ziopharm Oncology Inc (NASDAQ:ZIOP) Stock Attempts To Rebound After The Recent Fall

November 2, 2021

After the company made a key announcement yesterday, the Ziopharm Oncology Inc (NASDAQ:ZIOP) stock was on the move as investors moved into it and ended the day with gains of as much as 9%. Trading Data On Monday, ZIOP stock jumped 8.67% at $1.6300 with more than 1.51 million shares, compared to its average volume of 3.36 million shares. The stock has moved within a range of $1.5000 – 1.6300…


Ziopharm Oncology Inc (ZIOP) Stock Rockets To 1 Month High: What’s The Buzz?

September 8, 2021

Yesterday the Ziopharm Oncology Inc (NASDAQ:ZIOP) stock experienced heavy action and ended the day with gains of as much as 33%. The rally in the stock was triggered yesterday after the emergence of news with regards to certain filings made by Ziopharm with the United States Securities and Exchange Commission. The Form 4 filings that were made by the company revealed that some of the members of the Ziopharm board…


Ziopharm Oncology (ZIOP) Stock Recovers Sharply After The Recent Fall

September 2, 2021

One of the stock to have emerged as a major mover on Wednesday was that of Ziopharm Oncology (NASDAQ:ZIOP) as it ended the day with gains of as much as 10%. Considering the magnitude of the rally in the stock yesterday, it is perhaps time for investors to consider taking a closer look at Ziopharm and the reason behind the rally. Prior to yesterday’s rally, the stock had been a…


Ziopharm Oncology Inc (ZIOP) Stock Continues to Trend Lower: Down 29% in a Month

August 31, 2021

When a company makes a key appointment then it usually has an effect on its stock and shows how the market has taken the news. This brings us to the subject of the Ziopharm Oncology Inc (NASDAQ:ZIOP) stock, which tanked by as much as 7% after the company announced the appointment of its new Chief Executive Officer in the form of Kevin S. Boyle Sr yesterday. The appointment went into…


Ziopharm Oncology Inc. (NASDAQ:ZIOP) Stock Takes a Hit: A Good Buy Now?

August 11, 2021

Ziopharm Oncology Inc. (NASDAQ:ZIOP) fell 16% after announcing Q2 2021 corporate updates. Interim CEO Heidi Hagen said that Ziopharm had made considerable progress on various fronts since the last update. The company had built positive momentum in the TCR-T Library clinical study enabling activities and strengthening the balance sheet. He explained that the quarterly update shows that the company is on track with what it had early set to attain….